Context Therapeutics Inc.
Price Action
Technical Summary
CONSOLIDATINGContext Therapeutics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 3), showing significant lag compared to the market leaders. Earnings contraction of 80% provides fundamental context to the price action. However, RSI is deeply oversold at 20, suggesting potential for a mean-reversion bounce.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.23 | -54.15% | BELOW |
| 50 SMA | $1.94 | -70.84% | BELOW |
| 100 SMA | $2.27 | -75.12% | BELOW |
| 150 SMA | $2.00 | -71.68% | BELOW |
| 200 SMA | $1.78 | -68.19% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CNTX in an uptrend right now?
CNTX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is CNTX overbought or oversold?
CNTX's RSI (14) is 20. The stock is oversold (RSI < 30), which could indicate a bounce opportunity.
Is CNTX outperforming the market?
CNTX has a Relative Strength (RS) Rating of 3 out of 99. CNTX is currently lagging the broader market.
Where is CNTX in its 52-week range?
CNTX is trading at $0.57, which is 16% of its 52-week high ($3.62) and 1% above its 52-week low ($0.55).
How volatile is CNTX?
CNTX has a Beta of 0.22 and 52-week volatility of 101%. It's less volatile than the S&P 500 - generally more stable.